158 related articles for article (PubMed ID: 25744241)
1. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
Wang HC; Lee CS; Liu TC
Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
[No Abstract] [Full Text] [Related]
2. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Rasheed W; Flaim B; Seymour JF
Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
[No Abstract] [Full Text] [Related]
3. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
Yun S; Anwer F; Vincelette ND
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
[No Abstract] [Full Text] [Related]
4. Double-edged sword of the new cancer therapeutics.
Force T
Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
[No Abstract] [Full Text] [Related]
5. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary arterial hypertension in patients treated by dasatinib.
Montani D; Bergot E; Günther S; Savale L; Bergeron A; Bourdin A; Bouvaist H; Canuet M; Pison C; Macro M; Poubeau P; Girerd B; Natali D; Guignabert C; Perros F; O'Callaghan DS; Jaïs X; Tubert-Bitter P; Zalcman G; Sitbon O; Simonneau G; Humbert M
Circulation; 2012 May; 125(17):2128-37. PubMed ID: 22451584
[TBL] [Abstract][Full Text] [Related]
7. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
[No Abstract] [Full Text] [Related]
8. New drugs: paliperidone, dasatinib, and decitabine.
Hussar DA
J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
[No Abstract] [Full Text] [Related]
9. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
10. Drugs offer new hope for patients with CML who are resistant to imatinib.
Oestreicher P
ONS Connect; 2007 Jul; 22(7):20-1. PubMed ID: 17694781
[No Abstract] [Full Text] [Related]
11. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
12. Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
Roux C; Nicolini FE; Rea D; Niault M; Mollica L; Berger F; Chassagne-Clément C; Tigaud I; Tulliez M; Giraudier S; Turhan A; Rousselot P; Legros L
Blood; 2013 Oct; 122(17):3082-4. PubMed ID: 24159167
[No Abstract] [Full Text] [Related]
13. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
14. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Santos FP; Rodrigues M; Mac-Donald Bley do Nascimento C; Kerbauy FR; Ribeiro AA; Mauro Kutner J; Hamerschlak N
Cytotherapy; 2010; 12(1):113-5. PubMed ID: 19878083
[No Abstract] [Full Text] [Related]
15. Pulmonary hypertension in patients with chronic myeloid leukemia.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
[TBL] [Abstract][Full Text] [Related]
16. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Orlandi EM; Rocca B; Pazzano AS; Ghio S
Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
[No Abstract] [Full Text] [Related]
17. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
18. Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
Stagno F; Vigneri P; Di Raimondo F
Leuk Res; 2012 Jul; 36(7):803. PubMed ID: 22502918
[No Abstract] [Full Text] [Related]
19. Dasatinib in chronic myelogenous leukemia.
Kathula SK
N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
[No Abstract] [Full Text] [Related]
20. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Kim JC; Shin SH; Yi HG; Kim SH; Woo SI; Kim DH; Park KS; Kwan J
Herz; 2013 Dec; 38(8):931-3. PubMed ID: 23430094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
